Obesity and diabetes accelerate hepatocarcinogenesis via hepatocyte proliferation independent of NF-κB or Akt/mTORC1
Background: There are strong links between obesity, diabetes and hepatocellular carcinoma (HCC), but molecular mechanisms remain unclear.
Aims: We tested the proposed involvement of NF-kB, IL-6/STAT3 and Akt/mTORC1 before onset (at 3 months) and at onset (6 months) of accelerated hepatocarcinogenesis in DEN-injected obese and diabetic foz/foz compared to lean wildtype (Wt) mice, and also studied the hepatocyte proliferative response to DNA damage between the obese and lean lines.
Methods: Male foz/foz and Wt littermates fed normal chow were DEN-injected (10 mg/kg i.p.) at age 12-15 days. To test the effect of mTOR inhibitor on growth of dysplastic hepatocytes, a separate cohort of DEN-injected foz/foz mice was administered rapamycin (4 mg/kg body weight/day).
Results: foz/foz mice developed obesity, hyperinsulinemia, diabetes, adipokine dysregulation and fatty liver, without increased serum or liver TNF-α or serum IL-6. All DEN-injected foz/foz mice developed HCC by 6 mths vs. 0/10 lean Wt. At 3 mths, there were more dysplastic hepatocytes in DEN-injected foz/foz than Wt, with increased liver injury (serum ALT), hepatocyte apoptosis (M30-positive cells) and proliferation (cyclin D1, cyclin E, PCNA), but neither NF-kB nor STAT3 activation. foz/foz livers exhibited upregulation of DNA damage sensors ATM and ATR, with inadequate cell cycle checkpoint controls (CHK1, CHK2, p53, p21). Akt and mTORC1 were highly activated in livers from foz/foz vs. Wt mice. Despite such activation, rapamycin failed to reduce growth of dysplastic hepatocytes.
Conclusions: Accelerated DEN-induced HCC in obese/diabetic mice is linked to enhanced growth of dysplastic hepatocytes that cannot be attributed to NF-kB or IL-6/STAT3 activation, nor to sustained mTORC1 activation. The critical mechanism for obesity-enhanced hepatocarcinogenesis lies in the disconnection between hepatocellular injury with DNA damage, and an unrestrained proliferative response.
Relevance for patients: This study supports the epidemiological data linking obesity, diabetes and fatty liver disease with increased risk for developing HCC. The findings also suggest that mTORC1 inhibition may not be beneficial in the prevention of obesity-related hepatocarcinogenesis.
[1] Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: A meta-analysis of cohort studies. Br J Cancer 2007; 97: 1005-1008.
[2] Saunders D, Seidel D, Allison M, Lyratzopoulos G. Systematic review: The association between obesity and hepatocellular carcinoma-epidemiological evidence. Aliment Pharmacol Ther 2010; 31: 1051-1063.
[3] Tanaka K, Tsuji I, Tamakoshi A, Matsuo K, Ito H, Wakai K, Nagata C, Mizoue T, Sasazuki S, Inoue M, Tsugane S. Obesity and liver cancer risk: An evaluation based on a systematic review of epidemiologic evidence among the japanese population. Jpn J Clin Oncol 2012
[4] Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing il-6 and tnf expression. Cell 2010; 140: 197-208.
[5] Griffin TM, Huebner JL, Kraus VB, Guilak F. Extreme obesity due to impaired leptin signaling in mice does not cause knee osteoarthritis. Arthritis Rheum 2009; 60: 2935-2944.
[6] Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 2000; 68: 437- 446.
[7] Gruber S, Straub BK, Ackermann PJ, Wunderlich CM, Mauer J, Seeger JM, Buning H, Heukamp L, Kashkar H, Schirmacher P, Bruning JC, Wunderlich FT. Obesity promotes liver carcinogenesis via mcl-1 stabilization independent of il-6ralpha signaling. Cell Rep 2013; 4: 669-680.
[8] Chettouh H, Lequoy M, Fartoux L, Vigouroux C, DesboisMouthon C. Hyperinsulinemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma. Liver Int 2015
[9] Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011; 11: 886-895.
[10] Bhat M, Sonenberg N, Gores GJ. The mtor pathway in hepatic malignancies. Hepatology 2013; 58: 810-818.
[11] Laplante M, Sabatini DM. Mtor signaling in growth control and disease. Cell 2012; 149: 274-293.
[12] Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM. Pivotal role of mtor signaling in hepatocellular carcinoma. Gastroenterology 2008; 135: 1972-1983, 1983 e1971-1911.
[13] Zucman-Rossi J. Molecular classification of hepatocellular carcinoma. Dig Liver Dis 2010; 42 Suppl 3: S235-241.
[14] Menon S, Yecies JL, Zhang HH, Howell JJ, Nicholatos J, Harputlugil E, Bronson RT, Kwiatkowski DJ, Manning BD. Chronic activation of mtor complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signal 2012; 5: ra24.
[15] Umemura A, Park EJ, Taniguchi K, Lee JH, Shalapour S, Valasek MA, Aghajan M, Nakagawa H, Seki E, Hall MN, Karin M. Liver damage, inflammation, and enhanced tumorigenesis after persistent mtorc1 inhibition. Cell Metab 2014; 20: 133-144.
[16] Barash H, E RG, Edrei Y, Ella E, Israel A, Cohen I, Corchia N, Ben-Moshe T, Pappo O, Pikarsky E, Goldenberg D, Shiloh Y, Galun E, Abramovitch R. Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. Proc Natl Acad Sci U S A 2010; 107: 2207-2212.
[17] Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer 2006; 6: 674- 687.
[18] Pok S, Wen V, Shackel N, Alsop A, Pyakurel P, Fahrer A, Farrell GC, Teoh NC. Cyclin e facilitates dysplastic hepatocytes to bypass g1/s checkpoint in hepatocarcinogenesis. J Gastroenterol Hepatol 2013; 28: 1545-1554.
[19] Arsov T, Larter CZ, Nolan CJ, Petrovsky N, Goodnow CC, Teoh NC, Yeh MM, Farrell GC. Adaptive failure to high-fat diet characterizes steatohepatitis in alms1 mutant mice. Biochem Biophys Res Commun 2006; 342: 1152-1159.
[20] Heydet D, Chen LX, Larter CZ, Inglis C, Silverman MA, Farrell GC, Leroux MR. A truncating mutation of alms1 reduces the number of hypothalamic neuronal cilia in obese mice. Dev Neurobiol 2013; 73: 1-13.
[21] Van Rooyen DM, Larter CZ, Haigh WG, Yeh MM, Ioannou G, Kuver R, Lee SP, Teoh NC, Farrell GC. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 2011; 141: 1393-1403, 1403 e1391-1395.
[22] Larter CZ, Yeh MM, Van Rooyen DM, Teoh NC, Brooling J, Hou JY, Williams J, Clyne M, Nolan CJ, Farrell GC. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice. J Gastroenterol Hepatol 2009; 24: 1658-1668.
[23] Salomao M, Yu WM, Brown RS, Jr., Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (sh-hcc): A distinctive histological variant of hcc in hepatitis c virus-related cirrhosis with associated nafld/nash. Am J Surg Pathol 2010; 34: 1630- 1636.
[24] Ditch S, Paull TT. The atm protein kinase and cellular redox signaling: Beyond the DNA damage response. Trends Biochem Sci 2012; 37: 15-22.
[25] Bartek J, Lukas J. Chk1 and chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3: 421-429.
[26] Jabbur JR, Huang P, Zhang W. DNA damage-induced phosphorylation of p53 at serine 20 correlates with p21 and mdm-2 induction in vivo. Oncogene 2000; 19: 6203-6208.
[27] He G, Karin M. Nf-kappab and stat3 - key players in liver inflammation and cancer. Cell Res 2011; 21: 159-168.
[28] Bahrami BF, Ataie-Kachoie P, Pourgholami MH, Morris DL. P70 ribosomal protein s6 kinase (rps6kb1): An update. J Clin Pathol 2014; 67: 1019-1025.
[29] Shahbazian D, Parsyan A, Petroulakis E, Hershey J, Sonenberg N. Eif4b controls survival and proliferation and is regulated by proto-oncogenic signaling pathways. Cell Cycle 2010; 9: 4106- 4109.
[30] Inoki K, Zhu T, Guan KL. Tsc2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115: 577- 590.
[31] Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. Ampk phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008; 30: 214-226.
[32] Teoh NC, Dan YY, Swisshelm K, Lehman S, Wright JH, Haque J, Gu Y, Fausto N. Defective DNA strand break repair causes chromosomal instability and accelerates liver carcinogenesis in mice. Hepatology 2008; 47: 2078-2088.
[33] Hill-Baskin AE, Markiewski MM, Buchner DA, Shao H, DeSantis D, Hsiao G, Subramaniam S, Berger NA, Croniger C, Lambris JD, Nadeau JH. Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum Mol Genet 2009; 18: 2975-2988.
[34] Dowman JK, Hopkins LJ, Reynolds GM, Nikolaou N, Armstrong MJ, Shaw JC, Houlihan DD, Lalor PF, Tomlinson JW, Hubscher SG, Newsome PN. Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle. Am J Pathol 2014; 184: 1550-1561.
[35] Plentz RR, Park YN, Lechel A, Kim H, Nellessen F, Langkopf BH, Wilkens L, Destro A, Fiamengo B, Manns MP, Roncalli M, Rudolph KL. Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology 2007; 45: 968-976.
[36] Hytiroglou P, Park YN, Krinsky G, Theise ND. Hepatic precancerous lesions and small hepatocellular carcinoma. Gastroenterol Clin North Am 2007; 36: 867-887, vii.
[37] Kim H, Park YN. Role of biopsy sampling for diagnosis of early and progressed hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2014; 28: 813-829.
[38] Bakiri L, Wagner EF. Mouse models for liver cancer. Mol Oncol 2013; 7: 206-223.
[39] Bannasch P, Moore MA, Klimek F, Zerban H. Biological markers of preneoplastic foci and neoplastic nodules in rodent liver. Toxicologic Pathology 1982; 10: 19-34.
[40] Wang Y, Ausman LM, Greenberg AS, Russell RM, Wang XD. Nonalcoholic steatohepatitis induced by a high-fat diet promotes diethylnitrosamine-initiated early hepatocarcinogenesis in rats. Int J Cancer 2009; 124: 540-546.
[41] Vucur M, Reisinger F, Gautheron J, Janssen J, Roderburg C, Cardenas DV, Kreggenwinkel K, Koppe C, Hammerich L, Hakem R, Unger K, Weber A, Gassler N, Luedde M, Frey N, Neumann UP, Tacke F, Trautwein C, Heikenwalder M, Luedde T. Rip3 inhibits inflammatory hepatocarcinogenesis but promotes cholestasis by controlling caspase-8- and jnk-dependent compensatory cell proliferation. Cell Rep 2013; 4: 776-790.
[42] Maeda S, Kamata H, Luo JL, Leffert H, Karin M. Ikkbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121: 977-990.
[43] Dutta U, Kench J, Byth K, Khan MH, Lin R, Liddle C, Farrell GC. Hepatocellular proliferation and development of hepatocellular carcinoma: A case-control study in chronic hepatitis c. Hum Pathol 1998; 29: 1279-1284.
[44] Takai H, Naka K, Okada Y, Watanabe M, Harada N, Saito S, Anderson CW, Appella E, Nakanishi M, Suzuki H, Nagashima K, Sawa H, Ikeda K, Motoyama N. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J 2002; 21: 5195-5205.